Therapy options available for castration-resistant prostate cancer (CRPC) include secondary or more intensive hormone medicines, chemotherapy, immunotherapy, and radiation-related agents.

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

In patients with biochemical recurrence after prostate cancer surgery, the optimal duration of hormone therapy after salvage radiation therapy has been debated.

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on the phase 2 trial.

In a significant advancement for prostate cancer research, a first-of-its-kind study led by Emory researchers uncovered how ...

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

Drs Sandhya Srinivas and Tanya B. Dorff discuss metastatic hormone-sensitive prostate cancer, which patients are the best candidates for doublets vs triplets, and how we pick these patients.

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

In a significant advancement for prostate cancer research, a first-of-its kind study led by Emory researchers uncovered how ...

Prostate cancer is the most prevalent cancer in Australia. This article discusses the limitations of PSA tests in determining prostate cancer and highlights new guidelines for better detection and ...